Clinical dissection of multicentric Castleman disease

References

• Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956;9: 822–830.
   PubMed Web of Science ®Google Scholar
• Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 2005;129:3–17.
   PubMed Web of Science ®Google Scholar
• Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995;86:1276–1280.
   PubMed Web of Science ®Google Scholar
• Dupin N, Fisher C, Kellam P, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci USA 1999;96:4546–4551.
   PubMed Web of Science ®Google Scholar
• Parravicini C, Corbellino M, Paulli M, et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. Am J Pathol 1997;151:1517–1522.
   PubMed Web of Science ®Google Scholar
• Osborne J, Moore PS, Chang Y. KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. Hum Immunol 1999;60:921–927.
   PubMed Web of Science ®Google Scholar
• Aoki Y, Jaffe ES, Chang Y, et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 1999;93:4034–4043.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA. Treatment of Castleman's disease. Curr Treat Options Oncol 2005;6:255–266.
   PubMedGoogle Scholar
• Dham A, Peterson BA. Castleman disease. Curr Opin Hematol 2007;14:354–359.
   PubMed Web of Science ®Google Scholar
• Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer 1999;85:706–717.
   PubMed Web of Science ®Google Scholar
• Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001;92: 670–676.
   PubMed Web of Science ®Google Scholar
• Gerard L, Berezne A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol 2007;25:3350–3356.
   PubMed Web of Science ®Google Scholar
• Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 1998;128:657–662.
   PubMed Web of Science ®Google Scholar
• Kojima M, Nakamura N, Tsukamoto N, et al. Clinical implications of idiopathic multicentric castleman disease among Japanese: a report of 28 cases. Int J Surg Pathol 2008;16:391–398.
   PubMed Web of Science ®Google Scholar
• Dong Y, Na J, Lv J, et al. Clinical and laboratory characterization of a large cohort of patients with Castleman disease retrospectively collected from a single center. Leuk Lymphoma 2009;50:1308–1317.
   PubMed Web of Science ®Google Scholar
• Chun BY, Lee MK, Rho YK. The prevalence of hepatitis B surface antigen among Korean by literature review. Korean J Epidemiol 1992;14:70–78.
   Google Scholar
• Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865–1869.
   PubMed Web of Science ®Google Scholar
• Guihot A, Oksenhendler E, Galicier L, et al. Multicentric Castleman disease is associated with polyfunctional effector memory HHV-8-specific CD8+ T cells. Blood 2008;111: 1387–1395.
   PubMed Web of Science ®Google Scholar
• Waterston A, Bower M. Fifty years of multicentric Castleman's disease. Acta Oncol 2004;43:698–704.
   PubMed Web of Science ®Google Scholar
• Choe KW. Epidemiology of HIV/AIDS: current status, trend and prospect. J Korean Med Assoc 2007;50:296–302.
   Google Scholar
• World Health Organization. HIV/AIDS in Asia and the Pacific Region 2003. 1. HIV/AIDS status and trends in the Asia Pacific Region. GenevaWHO2004.
   Google Scholar
• Brenner H, Gondos A, Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood 2008;111:2977–2983.
   PubMed Web of Science ®Google Scholar
• Klimm B, Diehl V, Engert A. Hodgkin's lymphoma in the elderly: a different disease in patients over 60. Oncology (Williston Park) 2007;21:982–990; discussion 990, 996, 998 passim.
   PubMed Web of Science ®Google Scholar
• Mantovani G, Madeddu C, Gramignano G, et al. Association of serum IL-6 levels with comprehensive geriatric assessment variables in a population of elderly cancer patients. Oncol Rep 2004;11:197–206.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol 2010;8: 486–498.
   PubMedGoogle Scholar
• Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959–3964.
   PubMed Web of Science ®Google Scholar
• Andersen NS, Jensen MK, de Nully Brown P, Geisler CH. A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur J Cancer 2002;38:401–408.
   PubMed Web of Science ®Google Scholar
• Arya LS, Dinand V, Bakhshi S, Thavaraj V, Singh R, Dawar R. Significance of splenomegaly in childhood Hodgkin disease. J Pediatr Hematol Oncol 2004;26:807–812.
   PubMed Web of Science ®Google Scholar